BR112022010228A2 - Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas - Google Patents

Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas

Info

Publication number
BR112022010228A2
BR112022010228A2 BR112022010228A BR112022010228A BR112022010228A2 BR 112022010228 A2 BR112022010228 A2 BR 112022010228A2 BR 112022010228 A BR112022010228 A BR 112022010228A BR 112022010228 A BR112022010228 A BR 112022010228A BR 112022010228 A2 BR112022010228 A2 BR 112022010228A2
Authority
BR
Brazil
Prior art keywords
increased safety
safety characteristics
attenuated live
vaccines
leishmania parasite
Prior art date
Application number
BR112022010228A
Other languages
English (en)
Inventor
Matlashewski Gregory
Zhang Wen-Wei
Lypaczewski Patrick
L Nakhasi Hira
Dey Ranadhir
Gannavaram Sreenivas
Karmakar Subir
Satoskar Abhay
Original Assignee
Us Health
Ohio State Innovation Foundation
Matlashewski Gregory
Wen Wei Zhang
Lypaczewski Patrick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Ohio State Innovation Foundation, Matlashewski Gregory, Wen Wei Zhang, Lypaczewski Patrick filed Critical Us Health
Publication of BR112022010228A2 publication Critical patent/BR112022010228A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/10—Protozoa; Culture media therefor
    • C12N1/105—Protozoal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

VACINAS DE PARASITA DE LEISHMANIA VIVA ATENUADA COM CARACTERÍSTICAS DE SEGURANÇA AUMENTADAS. A presente invenção refere-se a espécies de Leishmania modificadas e suas composições, tais como organismos vivos e atenuados, composições imunogênicas, vacinas, e composições farmacêuticas. São descritos ainda métodos relacionados a espécies de Leishmania modificadas, tais como métodos de produção e métodos de uso.
BR112022010228A 2019-12-17 2020-12-17 Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas BR112022010228A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962949080P 2019-12-17 2019-12-17
PCT/US2020/065745 WO2021127271A1 (en) 2019-12-17 2020-12-17 Live attenuated leishmania parasite vaccines with enhanced safety characteristics

Publications (1)

Publication Number Publication Date
BR112022010228A2 true BR112022010228A2 (pt) 2022-09-06

Family

ID=74195109

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010228A BR112022010228A2 (pt) 2019-12-17 2020-12-17 Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas

Country Status (3)

Country Link
US (1) US20230039456A1 (pt)
BR (1) BR112022010228A2 (pt)
WO (1) WO2021127271A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113583876B (zh) * 2021-08-02 2024-07-09 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) EYFP敲入到Et.Actin基因的鸡柔嫩艾美尔球虫虫株的制备

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
WO2005021030A1 (en) * 2003-08-29 2005-03-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Live attenuated leishmania vaccines
FR2863272B1 (fr) * 2003-11-19 2006-06-09 Inst Rech Developpement Ird Nouveaux moyens pour la prevention des leishmanioses
US20050176144A1 (en) * 2004-02-06 2005-08-11 O'daly Jose A. Culture media compositions free of fetal bovine serum
FR2881752B1 (fr) * 2005-02-10 2009-07-31 Inst Rech Pour Le Dev I R D Et Moyens pour l'obtention de promastigotes de leishmanies avirulents, promastigotes obtenus et leurs applications
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
US20170306306A1 (en) 2014-10-24 2017-10-26 Life Technologies Corporation Compositions and Methods for Enhancing Homologous Recombination

Also Published As

Publication number Publication date
US20230039456A1 (en) 2023-02-09
WO2021127271A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
NI201900085A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
MY202765A (en) Triesters of cyclohexanetripropionic acid
UY37563A (es) Aislados de bacillus y usos de los mismos
CR20200082A (es) Virus chikungunya inmunogénico
BR112018070934A2 (pt) proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas
BR102014027442A8 (pt) Sequência recombinante, uso de uma planta, uma parte de planta, ou uma célula de planta de maís, método de preparação de uma célula vegetal transgênica e loci genômicos de maís não gênico purificados
EP4043031A3 (en) Zika viral antigen constructs
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
PH12019500989A1 (en) Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
BR112019008781A2 (pt) poxvírus quiméricos sintéticos
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
CR20170335A (es) Compuestos cíclicos sustituidos con un sistema de anillos condensados
DOP2018000209A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
CO2019010062A2 (es) Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens
PH12016502001A1 (en) Novel bacteriophage and composition comprising same
MX420767B (es) Proteina de union al factor h modificada
WO2016100615A3 (en) Methods and composition for neutralization of influenza
PH12019501173A1 (en) Attenuated swine influenza vaccines and methods of making and use thereof
BR112022010228A2 (pt) Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas
EA201990181A1 (ru) Получение активированных клостридиальных нейротоксинов
PH12016502000B1 (en) Novel bacteriophage and composition comprising same